Skip to Main Content

SAN FRANCISCO — AbbVie has halted an early-stage clinical trial testing an experimental cancer drug acquired in its takeover of Stemcentrx, the latest apparent failure from a high-flying biotech company backed by billionaire investor Peter Thiel.

The drug being tested, known as SC-007, is a type of antibody-drug conjugate, designed to home in on malignant cells while sparing healthy tissues.


The bad news for SC-007 comes after AbbVie announced disappointing results in March for Stemcentrx’s lead drug. That drug, another ADC called Rova-T, shrank tumors in too few patients and caused fluid to accumulate in the lungs when tested in a mid-stage study of patients with lung cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!